Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 34

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 34
---
 commercial success depends upon our ability, and the ability of our licensors and collaborators,
to develop, manufacture, market and sell product candidates and use proprietary technologies without infringing the proprietary rights
of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become
party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to potential
new products and technology, including proceedings challenging validity before the United States Patent and Trademark Office (“USPTO”)
and/or European Patent Office (“EPO”). Third parties may assert infringement claims against us based on existing patents or
patents that may be granted in the future.

If we are found to infringe a third party’s
intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing these
products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if
we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to
us. We could be forced, including by court order, to cease commercializing any infringing technology or product. In addition, we could
be found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have willfully infringed a
patent. A finding of infringement could prevent us from commercializing product candidates or force us to cease some of our business operations,
which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar negative impact on our business.

If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then in addition to seeking patents for the new technologies and product candidates, we also plan
to rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.
Any non-disclosure agreements (“NDAs”) or similar agreements entered into by the Company may not be with all relevant parties,
or adequately protect the confidentiality of our trade secrets. Moreover, to the extent we enter into such agreements, any of these parties
may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate
remedies for such breaches. Enforcing